These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. General strategies in in vivo animal modeling. Vallera DA; Blazar BR Targeted Diagn Ther; 1992; 7():63-77. PubMed ID: 1633310 [No Abstract] [Full Text] [Related]
3. [Protein engineering of Pseudomonas exotoxin and its targeting therapy of cancer]. Kondo T Tanpakushitsu Kakusan Koso; 1989 Oct; 34(13):1793-803. PubMed ID: 2513619 [No Abstract] [Full Text] [Related]
4. Monoclonal antibodies: does sufficient selectivity to cancer cells exist for therapeutic application? Oldham RK J Biol Response Mod; 1987 Jun; 6(3):227-34. PubMed ID: 3298552 [No Abstract] [Full Text] [Related]
5. Recombinant antibody fragments and immunotoxin fusions for cancer therapy. Brinkmann U In Vivo; 2000; 14(1):21-7. PubMed ID: 10757057 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of growth of human tumor xenografts in athymic mice treated with ricin toxin A chain-monoclonal antibody 791T/36 conjugates. Byers VS; Pimm MV; Scannon PJ; Pawluczyk I; Baldwin RW Cancer Res; 1987 Oct; 47(19):5042-6. PubMed ID: 3497715 [TBL] [Abstract][Full Text] [Related]
7. [Use of monoclonal antibodies in the immunotherapy of neoplasms]. Robak T Przegl Lek; 1989; 46(4):420-6. PubMed ID: 2672121 [No Abstract] [Full Text] [Related]
8. [Monoclonal antibodies: development and clinical prospects]. Borchmann P; Riethmüller G; Engert A Internist (Berl); 2001 Jun; 42(6):803-4, 807-14. PubMed ID: 11449627 [No Abstract] [Full Text] [Related]
9. [Antibody-conjugated cytostatic drugs. Uses of monoclonal antibodies for new strategies in tumor therapy]. Renner C; Pfreundschuh M Fortschr Med; 1994 Oct; 112(29):399. PubMed ID: 8001887 [No Abstract] [Full Text] [Related]
11. Toward an effective targeted chemotherapy for multiple myeloma. Polson AG; Sliwkowski MX Clin Cancer Res; 2009 Jun; 15(12):3906-7. PubMed ID: 19509145 [TBL] [Abstract][Full Text] [Related]
12. Whole ricin and recombinant ricin A chain idiotype-specific immunotoxins for therapy of the guinea pig L2C B cell leukemia. Gregg EO; Bridges SH; Youle RJ; Longo DL; Houston LL; Glennie MJ; Stevenson FK; Green I J Immunol; 1987 Jun; 138(12):4502-8. PubMed ID: 3495593 [TBL] [Abstract][Full Text] [Related]
13. [Immunotoxin: from the idea of "magic bullets" to clinical applications]. Engert A; Thorpe P Med Klin (Munich); 1990 Sep; 85(9):555-60. PubMed ID: 2233614 [No Abstract] [Full Text] [Related]
14. Cytokine targeting in tumors using a bispecific antibody directed against carcinoembryonic antigen and tumor necrosis factor alpha. Robert B; Mach JP; Mani JC; Ychou M; Folli S; Artus JC; Pèlegrin A Cancer Res; 1996 Oct; 56(20):4758-65. PubMed ID: 8840995 [TBL] [Abstract][Full Text] [Related]
15. [Recombinant immunotoxins and chimeric toxins for targeted therapy in oncology]. Chiron MF Bull Cancer; 1997 Dec; 84(12):1135-40. PubMed ID: 9587366 [TBL] [Abstract][Full Text] [Related]
16. Comparison of two anti-Thy 1.1-abrin A-chain immunotoxins prepared with different cross-linking agents: antitumor effects, in vivo fate, and tumor cell mutants. Thorpe PE; Blakey DC; Brown AN; Knowles PP; Knyba RE; Wallace PM; Watson GJ; Wawrzynczak EJ J Natl Cancer Inst; 1987 Nov; 79(5):1101-12. PubMed ID: 2890786 [TBL] [Abstract][Full Text] [Related]